Abbott Laboratories stock holds steady as CEO share sale and FDA diabetes approval shape outlook
Published on 08/28/2026 at 09:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories (ISIN US0028241000) stock has been trading in the low $110s as of August 26, 2026, with investors digesting a major insider share sale and updated 2026 earnings guidance that points to mid-single-digit EPS growth.
The shares closed at $114.11 on August 26, 2026, giving Abbott Laboratories a market capitalization of $197.45 billion and reflecting a 1.74 percent decline on the day according to a recent market-data overview stock chart and price history.
Alongside this modest pullback, the company now projects full-year 2026 earnings per share between $5.45 and $5.60, with analysts expecting $5.52, while recent commentary on a new US regulatory approval for its diabetes technology underscores the strategic importance of this fast-growing segment Q3 and FY 2026 guidance overview analysis of the diabetes approval and share performance.
CEO’s $46 million share sale adds to governance watchlist
A notable governance event arrived just ahead of the latest trading session, as Abbott Laboratories chairman and chief executive Robert B. Ford exercised stock options and sold a substantial block of shares in the open market during August 2026.
According to a recent regulatory filing summarized by StockTitan, Ford exercised employee stock options covering 398,832 common shares and subsequently sold all 398,832 shares in open-market transactions at volume-weighted average prices of $115.57 and $116.19 per share over multiple trades on August 25, 2026 summary of the insider Form 4 filing.
The transactions comprised one tranche of 218,535 shares at a weighted average price of $115.57 within a range of $115.09 to $116.08, and a second tranche of 180,297 shares at a weighted average price of $116.19 within a range of $116.09 to $116.36, implying proceeds in excess of $46 million from the combined sales note on the CEO share sale.
For investors, the magnitude and timing of this sale are notable because they occurred with Abbott Laboratories stock trading just below the mid-$110s, a level that broadly matches recent price action and sits only a few dollars above consensus valuation benchmarks.
Guidance points to steady EPS growth in 2026
While the insider sale has captured attention, the fundamental backdrop for Abbott Laboratories remains anchored by its latest forward guidance for 2026 earnings, which emphasizes moderate growth supported by its medical devices and diagnostics franchises.
Per recent guidance commentary, Abbott Laboratories has set its full-year 2026 adjusted EPS outlook in a range of $5.45 to $5.60, with the midpoint of $5.525 representing a modest increase versus the current-year baseline; sell-side consensus currently clusters around $5.52 per share for the year, closely aligned with management’s midpoint overview of EPS guidance and expectations.
The company has also outlined Q3 2026 guidance with an EPS range of $1.38 to $1.46, indicating a step-up from prior quarters and implying annualized profitability that supports the full-year target; this corridor offers room for upside relative to consensus, which foresees quarterly EPS of $1.43 and revenue of $12.91 billion, pointing to expected year-over-year revenue growth of 13.52 percent in the upcoming quarter consensus snapshot on the upcoming quarter and full-year estimates.
For 2026 as a whole, consensus estimates project Abbott Laboratories to deliver earnings of $5.52 per share and revenue of $50.18 billion, which would correspond to EPS growth of 7.18 percent and revenue growth of 13.19 percent compared with the prior year; this pairing of high-single-digit earnings expansion and low-teens top-line growth suggests a balanced trajectory between margin stability and volume gains detail on 2026 EPS and revenue forecasts.
Analysts’ view of Abbott Laboratories remains supportive under this guidance framework, with a prevailing consensus rating described as moderate buy and an average price target of $119.50, pointing to prospective upside of roughly $7.50 or around 6.7 percent relative to the recent $112 zone; this spread frames the shares as trading at a modest discount to the implied fair value in current models analyst rating and price target summary.
Q2 2026 margin trends and diabetes franchise underpin the moat
Beneath the top-level guidance, Abbott Laboratories’ latest reported quarter offers further clues to its economic moat and profit trajectory, particularly in medical devices and diabetes care.
An economic moat analysis published in late August describes how Abbott’s Q2 2026 performance reflected solid margin dynamics, with adjusted gross margin reaching 58.0 percent in the quarter, a 100 basis-point improvement year over year; this margin expansion is credited to improved product mix and contributions from partnerships in diagnostic testing, underscoring pricing power in key segments analysis of economic moat and Q2 2026 margins.
Within devices, segment divergence is highlighted: medical devices are reported to have grown 8.4 percent in Q2 2026, while diabetes care expanded 9.5 percent, driven by the FreeStyle Libre continuous glucose monitoring platform generating sales above $2 billion in the quarter; these growth rates and revenue levels point to diabetes care as a core moat component, even as other segments such as nutrition face more muted trends breakdown of segment growth and Libre revenue.
Operating metrics reinforce this picture: the Q2 2026 adjusted gross margin of 58.0 percent occurred alongside disciplined spending levels, with sales and marketing and research and development ratios described as stable; together, the data suggest Abbott Laboratories is translating its diabetes and devices franchise strength into durable profitability that underpins the 2026 EPS guidance corridor.
This operating resilience appears particularly relevant in light of the recent US Food and Drug Administration decision that granted Abbott Laboratories a first-of-its-kind approval related to diabetes care; recent coverage notes that the FDA action, framed as a diabetes first, has begun to support sentiment for the stock after a period of weakness, with the shares advancing 9.2 percent over the past month to $114.10 and trimming a year-over-year decline of 11.29 percent and a year-to-date drop of 7.25 percent discussion of FDA diabetes approval and share performance.
Valuation and recent share performance
From a valuation standpoint, Abbott Laboratories stock’s recent trading range in the low to mid-$110s positions it modestly below the consensus price target while still reflecting the premium investors typically assign to diversified medical technology companies with recurring revenue streams.
As of the latest chart snapshot on August 26, 2026, the closing price of $114.11 compares to the consensus target of $119.50, leaving room for potential appreciation if the company delivers on its EPS and revenue guidance; the recent intraday quote of $112.08 as of 12:11 p.m. Eastern in a separate price overview indicates modest volatility around this range, with the shares down 1.77 percent at that time and roughly 10.6 percent below the level they held a year earlier real-time price overview and one-year performance data.
Recent commentary also notes that Abbott Laboratories has lagged the broader market over the past year and year to date, with declines of 11.29 percent over twelve months and 7.25 percent since the start of 2026, respectively, even as a 9.2 percent rally in the last month suggests improving sentiment following the FDA diabetes approval; this mix of underperformance on longer horizons and short-term recovery highlights how catalysts and execution around core growth franchises can quickly reshape the narrative for defensive healthcare names performance detail relative to recent catalysts.
Investors considering the stock therefore face a trade-off between current valuation discount versus consensus and the need for sustained delivery on 2026 guidance, particularly in segments where competition is intensifying; the insider sale by the CEO may be interpreted variously, but the data so far show that guidance, margins, and regulatory momentum in diabetes care continue to support the long-term earnings story.
FreeStyle Libre anchors Abbott’s diabetes strategy
One of Abbott Laboratories’ most visible products, FreeStyle Libre, sits at the heart of the company’s diabetes strategy and has become a cornerstone of its economic moat in recent years.
FreeStyle Libre is a continuous glucose monitoring system designed to help people with diabetes track their glucose levels through a sensor worn on the body and a reader or compatible smartphone; recent analysis of Abbott’s Q2 2026 results indicates that Libre’s revenue exceeded $2 billion in the quarter and that the diabetes care segment as a whole grew 9.5 percent, underscoring the product’s ability to drive both top-line expansion and recurring device utilization discussion of Libre revenue contribution.
The platform’s growth is further supported by the recent FDA move granting Abbott Laboratories a diabetes-related first, described as a regulatory action that strengthens the company’s standing in continuous glucose monitoring and broader diabetes management solutions; coverage notes that the market has begun to respond to this approval, with the stock’s 9.2 percent one-month rally coinciding with renewed interest in the Libre franchise and its potential to extend Abbott’s competitive edge overview of diabetes platform and FDA development.
For users, FreeStyle Libre’s key appeal lies in reduced fingerstick testing and more continuous visibility into glucose trends, which can improve adherence and outcomes; for Abbott Laboratories, the device’s market penetration supports recurring revenue streams and enhances the sustainability of its medical devices segment, which grew 8.4 percent in Q2 2026 and remains a central pillar in the company’s long-term strategy.
Abbott Laboratories stock and recent price context
Abbott Laboratories stock is listed on the New York Stock Exchange under the ticker ABT and is commonly considered part of the US large-cap healthcare universe, with exposure to indices such as the S&P 500 and a mix of defensive and growth characteristics in investor portfolios.
As of August 26, 2026, the closing price of $114.11 and market cap of $197.45 billion place Abbott Laboratories in the upper tier of global medical technology issuers by size; intraday price data showing a quote of $112.08 as of 12:11 p.m. Eastern in a recent snapshot highlight that the shares have traded slightly below that closing level, reflecting a 1.77 percent decline on the day and signaling some short-term volatility around the low-$110 zone chart-based closing price and market cap data intraday price and percentage move data.
Combined with the consensus price target of $119.50 and analysts’ projection of $5.52 in EPS and $50.18 billion in revenue for 2026, this price context suggests that Abbott Laboratories stock currently trades at a discount to its modeled fair value and embeds expectations for continued growth in devices and diagnostics; the recent FDA diabetes approval and strong Q2 2026 margin trends provide quantitative support for that narrative, even as the sizable CEO share sale reminds investors to watch governance and insider activity closely.
Read more
More on Abbott Laboratories stock
FreeStyle Libre expands global diabetes reach
FreeStyle Libre, Abbott Laboratories’ flagship continuous glucose monitoring system, exemplifies the company’s focus on patient-centric innovation in diabetes care and has played a central role in its recent growth.
In Q2 2026, diabetes care revenue growth of 9.5 percent and Libre sales above $2 billion underscore both strong demand and the product’s ability to scale across geographies and care settings; the associated margin contributions help support the company’s adjusted gross margin of 58.0 percent in the quarter and its full-year EPS guidance range of $5.45 to $5.60 insight on Libre-driven growth and margin impact.
With the recent FDA action granting Abbott Laboratories a notable diabetes-related approval, Libre is positioned to extend its franchise further, bolstering the moat that analysts observe around Abbott’s medical devices and diagnostics businesses and potentially supporting the consensus view that earnings of $5.52 per share and revenue of $50.18 billion are achievable in 2026.
Price level frames investor decisions
Against this backdrop of insider activity, guidance, and product strength, the current price level of Abbott Laboratories stock serves as a key reference point for investors evaluating risk and reward.
The closing price of $114.11 on August 26, 2026, together with an intraday quote of $112.08 as of 12:11 p.m. Eastern in a subsequent session, places the shares modestly below the $119.50 consensus target and reflects a one-year decline of 10.6 percent from earlier levels; these figures collectively indicate that the stock has given back gains over the past year but retains multi-billion-dollar scale and a growth outlook anchored in diabetes and devices one-year performance and valuation context.
For retail investors, the combination of a large CEO share sale at prices around $115 to $116 per share, a 2026 EPS guidance range reaching up to $5.60, and a recent FDA diabetes approval presents a nuanced picture: governance and insider dynamics require monitoring, yet the quantitative trends in margins, segment growth, and consensus earnings expectations continue to support Abbott Laboratories’ long-term role as a major healthcare issuer.
Fact box
Company: Abbott Laboratories Inc.
ISIN: US0028241000
Ticker: ABT
Exchange: NYSE
Price (as of August 26, 2026, 3:58 p.m. ET): $114.11 USD
Market cap: $197.45 billion (as of August 26, 2026)
Sector / Industry: Health care / Medical devices and diagnostics
Index membership: S&P 500
